A mutant version of p53 (p53-121F), in which phenylalanine replaces the 121st serine residue, can induce apoptosis more effectively than wild-type p53 (wt-p53). In view of this observation, we considered that one or more apoptosis-related p53-target genes might be preferentially induced by p53-121F. We carried out cDNA microarray analysis to identify such genes, using mRNAs isolated from LS174T colon-cancer cells infected by adenovirus vectors containing either p53-121F (Ad-p53-121F) or wtp53 (Ad-p53). The STAG1 gene was one of the transcripts showing higher expression levels in cells infected with Adp53-121F as opposed to Ad-wtp53. The encoded product appears to contain a transmembrane domain, and binding motifs for SH3 and WW. In two other cancer cell lines, the expression of STAG1 mRNA was induced in response to various genotoxic stresses in a p53-dependent manner; moreover, enforced expression of STAG1 led to apoptosis in several additional cancer cell lines. Suppression of endogenous STAG1 using the RNA-interference method reduced the apoptotic response, whether induced by Adp53-121F or Ad-p53. These results suggest that STAG1, a novel transcriptional target for p53, mediates p53-dependent apoptosis, and might be a good candidate for next-generation gene therapy.
Introduction
The most frequently mutated gene in human tumors is p53 (Baker et al., 1990; Hollstein et al., 1991) . Its product, a transcription factor, plays a critical role as a proficient inhibitor of cell growth through regulation of a number of downstream genes. The tumor-suppressive activities of p53 protein are generally classified into two categories (El-Deiry et al., 1993; Harper et al., 1993; Xiong et al., 1993) , that is, inhibition of cell-cycle progression and induction of apoptosis. This protein is involved in various physiological mechanisms in response to DNA damage and cellular stress; for example, it transactivates target genes such as p53AIP1 to mediate apoptosis (Oda et al., 2000) , p21
waf1 to arrest the cell cycle (El-Deiry et al., 1993) and p53R2 to repair DNA .
To clarify p53 functions in detail with a view to apply ultimately the information to cancer therapy, we earlier isolated several novel p53-target genes using a yeast enhancer-trap system (Furuhata et al., 1996; Nishimori et al., 1997; Urano et al., 1997; Han et al., 1998) ; a differential-display method (Takei et al., 1998; Ng et al., 1999; Oda et al., 2000; Tanaka et al., 2000) ; or cDNAmicroarray technology (Iiizumi et al., 2002; Ochi et al., 2002; Mori et al., 2002a, b) . In the course of these studies, we showed that adenovirus-mediated expression of p53AIP1 could induce tumor suppression more effectively than p53 itself (Matsuda et al., 2002) .
Although gene therapy using adenovirus-p53 already has clinical applications for clinical cancer therapy, the results reported so far have not been promising (Roth et al., 1996; Habib et al., 1999; Weill et al., 2000) . One reason for this may be insufficient modification of p53, particularly phosphorylation at Ser15, Ser20 and Ser46. We previously reported that the expression of p53AIP1 was regulated by phosphorylation of p53 protein at the 46th serine residue, through interaction with p53DINP1. Without modification of certain residues, the p53 protein is unlikely to induce apoptosis effectively; but after appropriate post-translational modification p53 can transactivate mediators of apoptosis.
An altered form of p53, p53-121F, in which the 121st serine residue of p53 is replaced by phenylalanine, was originally selected in yeast, as a p53-mutant with increased transcriptional activity toward genes with a sequence similar to the p53-binding site of the BAX gene (Freeman et al., 1994) . These results suggested that p53-121F possessed a greater ability to induce apoptotic activity through a combination of reduced induction of MDM2 and transactivation of an alternative set of p53-target genes (Saller et al., 1999) . We considered that p53-121F could be a constitutively active form of p53 protein, and used a cDNA microarray to search for genes that might be preferentially activated by p53-121F.
In the work reported here, we demonstrated that STAG1 was strongly induced by p53-121F, and that enforced expression of STAG1 using a recombinant adenovirus vector effectively induced apoptosis in several cancer cell lines, probably through the mitochondrial apoptotic pathway. Moreover, our data suggest that STAG1, as a novel mediator of p53-dependent apoptosis, could become part of a new strategy for gene therapy.
Results
We screened a cDNA microarray for genes whose expression was more strongly enhanced by exogenous p53-121F than by wild-type p53 (wt-p53). Among dozens of candidate genes identified in this way, we confirmed by Northern blot analysis that mRNA of STAG1 was transactivated by the induction of exogenous p53 in LS174T cells and enhanced by exogenous p53-121F; major transcripts of 4.0 and 2.0 kb were induced by p53, but signal intensities were much greater after induction by p53-121F (Figure 1a ). To investigate whether STAG1 was a direct target for p53, we searched for p53-binding motifs (p53BS) in its genomic sequence. A possible p53BS, with a 90% match to the consensus p53BS, was found in intron 1 (Figure 1b) , and the ChIP assay indicated that both p53 and p53-121F proteins could bind to this sequence in vivo (Figure 1c) .
We then examined whether the transcription of STAG1 could be activated by endogenous p53 in response to DNA damage (UV irradiation, ionizing radiation or adriamycin treatment) using two cell lines, one containing wt-p53 (MCF7) and the other lacking wt-p53 (H1299) (Figure 2a ). The expression of STAG1 was increased in MCF7 (wt-p53) cells in a timedependent manner, but not in H1299 cells (p53 null) after exposure to each form of genotoxic stress, especially ionizing radiation. Moreover, the expression of endogenous SATG1 protein was induced in response to UV radiation in a dose-dependent manner and the expression level was closely related to the extent of apoptosis (Figure 2b ), suggesting that STAG1 is involved in DNA damage-inducing apoptosis.
To verify a function of STAG1 in the regulation of cell growth, we carried out colony-formation assays using vectors designed to express sense or antisense strands of STAG1. Each of these expression vectors, or empty vector (mock), was transfected into HCT116 (wtp53), H1299 (p53 null) or T98G (mutant p53) cells. Fewer colonies grew after transfection of sense-STAG1 into all three cell lines (Figure 3a, b) . To explore further whether this effect should be attributed to cell-cycle arrest or to induction of apoptosis, we constructed adenovirus vectors containing STAG1 cDNA, transfected them to several cancer cell lines and then evaluated apoptotic cells by the TUNEL assay. Figure 4 shows the expression of STAG1 and p53 at various multiplicity of infections (MOIs) in LS174T cells after immunoblotting. As shown in Figure 4 , infection with Ad-STAG1 drastically increased the population of apoptotic cells. To evaluate the apparent apoptosisinducing activity of STAG1, we transfected Ad-STAG1 to cancer cell lines derived from a variety of tissues, with or without p53 mutations: LS174T, HCT116 (p53
), A549, LC176, U373, A172 and HepG2. All eight cell lines showed 100% infectivity of the Ad-LacZ vector at an MOI of 20 and higher.
Among the eight cell lines tested, Ad-STAG1 induced apoptosis more effectively than Ad-p53 in three (LS174T, A549, LC176) ( Figure 5 ). In four lines
, U373MG, HepG2), Ad-STAG1 and Ad-p53 revealed similar apoptosisinducing activities, and neither induced apoptosis in one line (A172).
We then examined the expression or activation of some apoptosis-related proteins by Western blot analysis, in order to shed some light on the molecular Figure 4 , Ad-STAG1 infection activated caspase-9, an enzyme involved in the mitochondrial apoptotic pathway.
We applied RNA-interference (RNAi) technology to confirm a role of endogenous STAG1 in p53-121F-and p53-induced apoptosis. We pretreated LS174T cells with pSUPER-STAG1, designed to express siRNA, or with pSUPER-GFP, which expresses siRNA corresponding to the GFP gene. The first of these plasmid constructs partially inhibited the expression of STAG1 protein and subsequently suppressed the apoptosis induced by Adp53-121F and Ad-p53 (Figure 6 ), suggesting that STAG1 might play a role, to some extent, in p53-121F-and p53-induced apoptosis. Rae et al. (2001) reported overexpression of the STAG1 gene in solid tumors, an indication of an oncogenic role, but these data were apparently contradictory to ours. To address this question, we analysed the expression of STAG1 in 16 cancer cell lines by immunoblotting, using anti-STAG1 antibody ( Figure 7) . As shown in Figure 7 , the expression levels of endogenous STAG1 in the cancer cell lines examined were much lower than those of exogenous STAG1 (lanes of control). Moreover, the molecular weight of STAG1 protein expressed in the cancer cells appeared to be equivalent to the smallest of the four forms of STAG1 protein induced by Ad-p53 or Ad-p53-121F. These results suggested that the elevated expression level and post-translational regulation of STAG1 protein might be essential for acquiring apoptosis-inducing activity.
Discussion
Earlier experiments in our laboratory implied that the decision determining cell fate, that is, cell-cycle arrest or apoptosis, can be determined by modification (phosphorylation or acetylation) of p53 protein and subsequent selection of alternatives among downstream target genes (Oda et al., 2000; Yamaguchi et al., 2001; Matsuda et al., 2002) . A mutant form of p53, p53-121F, is dominant for inducing apoptosis (Saller et al., 1999) . We considered that the conformation of the mutant protein could be similar to that of modified p53 proteins that show enhanced apoptosis-inducing activity in vivo for eliminating dangerous cells. Hence, genes that are preferentially transactivated by p53-121F are likely to be good candidates as mediators of p53-dependent apoptosis.
Others have reported elevated expression of the STAG1 gene in solid tumors, suggesting an oncogenic function (Rae et al., 2001) . In contrast to that report, our data indicated that the ectopic expression of STAG1 has significant apoptosis-inducing activity. One reason for the contradictory results might be different posttranslational regulation of the proteins, because during 
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Y Anazawa et al the process in STAG1-induced apoptosis we observed four different molecular sizes of the STAG1 protein, but only the form corresponding to the smallest weight was detected in the cancer cell lines we examined. A murine counterpart for STAG1, Nedd4WW-binding protein 4 (Murillas et al., 2002) appears to be a ubiquitin-protein ligase that is cleaved by caspases during apoptosis (Harvey et al., 1998) . Nedd4 in the mouse may be required to mediate the normal turnover of proteins required for apoptotic function. Evidence from the murine model seems to coincide with our hypothesis, which suggests that endogenous STAG1 protein is constitutively cleaved by some proteases and is present in cleaved forms in cancer cell lines, but its apoptosisinducing activity is exerted through a mitchondrial pathway. Although the detailed molecular mechanism involved in STAG1-associated apoptosis is unclear, the fact that Ad-STAG1 was able to induce apoptosis more effectively than Ad-p53 in some cancer cell lines could indicate the potential usefulness of the STAG1 gene in cancer therapy.
Materials and methods

Cell lines and recombinant adenovirus
Human cancer cell lines LS174T (colon cancer, wt-p53), SW480 (colon cancer, mt-p53), U373 (glioblastoma, mt-p53), U87MG (glioblastoma, wt-p53), A172 (glioblastoma, wt-p53), NCl-H23 (lung cancer, mt-p53), A549 (lung cancer, wt-p53), H1299 (lung cancer, mt-p53), LC176 (lung cancer, wt-p53), MDA-MB-231 (breast cancer, mt-p53) MCF7 (breast cancer, wt-p53), HepG2 (hepatoma, wt-p53) and HEK293 (primary human embryonic kidney) were purchased from the American Type Culture Collection (ATCC). TE6 (esophageal cancer, mtp53) was obtained from the Cell Resource Center for Biomedical Research, Tohoku University. T98G (glioblastoma, mt-p53) was obtained from the Japanese Collection of Research Bioresources (JCRB). HCT116 (p53 þ / þ ) and HCT116 (p53 À/À ) were gifts from Dr B Vogelstein. All cells were cultured under conditions recommended by their depositors.
Recombinant adenoviruses containing cDNAs of LacZ (AdLacZ), p53 (Ad-p53), 121F mutant p53 (Ad-p53-121F) or STAG1 (Ad-STAG1) were generated as described previously (McGrory et al., 1988) .
cDNA microarray LS174T cells were infected with Ad-LacZ, Ad-p53 or Ad-p53-121F, at 80 MOI. Total RNAs were isolated from each cell line 24 and 48 h later, using TRIzol reagent (Life Technologies). Poly(A) þ RNA was purified from each total RNA using mRNA purification kits (Amersham), then amplified with Ampliscribe T7 Transcription kits (Epicentre Technologies).
The preparation of probes, hybridization procedures and scanning methods were described previously (Ono et al., 2000) . In brief, an adequate amount of each amplified RNA was labeled with Cy3 or Cy5 based on reverse transcription, and then the probes were cohybridized to a cDNA microarray. The intensity of fluorescence on each spot was normalized to the mean of 52 housekeeping genes. We characterized genes that showed an increased expression in response to exogenous p53 
DNA-damaging treatments
MCF7 and H1299 cells were subjected to UV irradiation at 10 J/m 2 using a UV crosslinker (Stratagene), ionizing radiation at 50 Gy or treatment with 1 mg/ml adriamycin (Kyowa Hakko Kogyo). Total RNA was extracted from the cells at selected times after treatment, and the expression of STAG1 was examined by Northern blotting.
Northern blotting
A 2-mg aliquot of each poly(A)
þ RNA was electrophoretically separated on a 1% agarose gel containing 1 Â MOPS buffer and 2% formaldehyde, and blotted onto a nylon membrane. The membrane was hybridized with randomly labeled 32 P-STAG1, p21 or b-actin cDNA, washed twice with 0.1 Â SSC/ 0.1% SDS at 651C and exposed for autoradiography at À801C.
Chromatin immunoprecipitation assay
ChIP assays were performed using the Acety-Histone H3 ChIP Assay Kit (Upstate Biotechnology) as recommended by the manufacturer, except that we used antibodies against p53 (DO-7) and a FLAG-tag peptide (M2, Sigma). LS174T cells (1 Â 10 6 ) were plated onto 10-cm dishes and infected with Adp53 or Ad-p53-121F at an MOI of 80. After 24 h, 1% formaldehyde (final concentration) was added directly to the dishes to crosslink genomic DNA and protein, with incubation at 371C for 15 min. Cells were collected in 1 ml PBS containing Complete Protease Inhibitor (Roche), then lysed in 200 ml SDS lysis buffer. Sonication generated genomic fragments 200-1000 bp long. After centrifugation, each supernatant was diluted 10-fold with ChIP dilution buffer and incubated with a specific antibody at 41C for 16 h under rotation. Immune complexes were precipitated, washed and eluted as recommended. DNA-protein crosslinks were reversed by heating at 651C for 4 h; the DNA was recovered by phenol/chloroform extraction and ethanol precipitation before suspension in 50 ml of TE. A 5-ml aliquot of each sample was used as the template for PCR amplification.
Colony-formation assay
The coding sequence of STAG1 was inserted into pcDNA 3.1( þ ) or pcDNA 3.1(À) vectors (Invitrogen). A total of 8 mg of each vector, and empty vector (mock), were transfected with FuGENE6 reagent (Roche) into 5 Â 10 5 cells of HCT116 (p53 þ / þ ), T98G or H1299 in 10-cm dishes and cultured overnight. After 2 days, cells were trypsinized and replated in quantities of 2 Â 10 4 , 1 Â 10 4 or 5 Â 10 3 cells on 10-cm dishes with a medium containing 0.8 mg/ml G418, cultured for 10-20 days and stained with crystal violet.
Detection of apoptosis
For FACS analysis, adherent and detached cells were combined and fixed with 70% ethanol for 30 min at 41C. After treatment with 2 mg/ml RNase for 30 min at 371C, cells were stained with PBS containing 100 mg/ml propidium iodide. The percentages of sub-G 1 nuclei in each population were determined from at least 2 Â 10 4 cells in a flow cytometer (FACScalibur; Becton Dickinson).
TUNEL analyses were performed using Apoptag Fluorescein Direct In situ Apoptosis Detection Kits (INTERGEN) according to the procedure recommended by the manufacturer.
Antibodies and immunoblotting
Polyclonal antibody against STAG1 protein was generated in rabbits using a synthesized STAG1 peptide (NH 2 -SRHSQGRREDALS-COOH); this antibody was affinity purified on a column conjugated with the same peptide. Mouse monoclonal antibody against b-actin and rabbit polyclonal antibody against caspase-9 were purchased from SIGMA and BD Pharmingen, respectively. Immunoblotting was performed as described previously (Oda et al., 2000) .
RNA interference
To suppress the endogenous expression of STAG1, we performed RNAi using pSUPER vector. pSUPER-STAG1 si2 (only the sense sequence: 5 0 -GCTGGAACTGAACCGG-GAG-3 0 ) and, as controls, we prepared pSUPER-GFP (5 0 -GTTCGACAGCGTCTCCGAC-3 0 ) and pSUPER-STAG1 si1 (5 0 -TCACGGAGCTGGAGTTTGT-3 0 ) constructs. Plasmid DNAs were introduced to LS174T cells by electroporation; 48 h later, 3 Â 10 5 cells were plated in six-well plates. After 24 h, the cultured cells were infected with Ad-p53-121F at an MOI of 50 or 100. Whole-cell extracts were prepared 24 h later, separated on 10% SDS-PAGE and analysed by immunoblotting using anti-STAG1 antibody. Plasmid-infected cells were subjected to FACScan analysis 48 h later.
